实用老年医学

实用老年医学 ›› 2021, Vol. 35 ›› Issue (6): 609-611.doi: 10.3969/j.issn.1003-9198.2021.06.019

• 临床研究 • 上一篇    下一篇

噻托溴铵联合沙美特罗替卡松治疗老年稳定期慢性阻塞性肺疾病的疗效及药物经济学评价

吴玲, 张丹丹, 谢龙, 黄莉   

  1. 210024 江苏省南京市,南京医科大学附属老年医院药剂科
  • 收稿日期:2020-07-21 发布日期:2021-06-29
  • 通讯作者: 黄莉,Email: njhl2013@163.com
  • 基金资助:
    江苏省药学会-天晴医院药学科研项目(Q2018049);江苏卫生健康职业学院院级科研项目(JKA201704)

Efficacy and pharmacoeconomic evaluation of tiotropium bromide combined with salmeterol/fluticasone in elderly patients with stable chronic obstructive pulmonary disease

WU Ling, ZHANG Dan-dan, XIE Long, HUANG Li   

  1. Department of Pharmacy, Geriatric Hospital of Nanjing Medical University, Nanjing 210024, China
  • Received:2020-07-21 Published:2021-06-29

PDF (PC)

758

摘要： 目的 评价噻托溴铵联合沙美特罗替卡松治疗对老年稳定期COPD病人的肺功能和圣乔治呼吸问卷(SGRQ)评分的影响并进行药物的成本-效果分析。方法 选取2017年8月至2018年8月我院收治的老年稳定期COPD病人60例,随机分为观察组和对照组,每组30例。对照组病人采用沙美特罗替卡松治疗,观察组病人采用噻托溴铵联合沙美特罗替卡松治疗。治疗6个月后,比较2组病人治疗前后的肺功能、SGRQ评分、COPD急性加重次数,并对2种治疗方案进行成本-效果分析。结果 干预后,观察组FEV1及FVC高于对照组,SGRQ评分低于对照组,差异有统计学意义(P<0.05)。2组间FEV1/FVC差异无统计学意义(P>0.05)。观察组成本-效果比(C/E)明显优于对照组,差异有统计学意义(P<0.05)。结论 噻托溴铵联合沙美特罗替卡松用于治疗老年稳定期COPD病人,能够显著改善病人的肺功能和SGRQ评分,且具有较好的成本-效果。

关键词: 慢性阻塞性肺疾病, 老年人, 噻托溴铵, 药物经济学

Abstract: Objective To evaluate the effects of tiotropium bromide combined with salmeterol/fluticasone on lung function and St. George’s respiratory questionnaire (SGRQ) score in the elderly patients with stable chronic obstructive pulmonary disease (COPD), and to analyze the cost-effectiveness. Methods A total of 60 patients with stable COPD were randomly divided into the observation group(n=30) and the control group(n=30). The control group was treated with salmeterol/fluticasone and the observation group were treated with tiotropium bromide combined with salmeterol/fluticasone. After six months of treatment, the lung function, SGRQ score, number of acute exacerbations were compared between the two groups, and a cost-effectiveness analysis was performed for the two treatment options. Results After the intervention, the levels of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in the observation group were higher than those in the control group, and the SGRQ score was lower than that in the control group (P<0.05). FEV1/ FVC showed no significant differences between two groups (P> 0.05). The cost-effectiveness analysis showed that the cost-effectiveness ratio (C/E) of the observation group was significantly better than that of the control group (P<0.05). Conclusions The regimen of tiotropium bromide combined with salmeterol/fluticasone for the treatment of stable COPD in the elderly patients can significantly improve the lung function and SGRQ score, reduce the number of acute exacerbations, which shows better cost-effectiveness.

Key words: chronic obstructive pulmonary disease, aged, tiotropium bromide, pharmaceutical economics

中图分类号: